Brand Intelligence Graph
Company Overview
About Xaira Therapeutics
Xaira Therapeutics is an AI-powered drug discovery company launched from stealth in April 2024 with $1 billion in committed capital. Headquartered in South San Francisco, incubated by Arch Venture Partners and Foresite Capital. Led by CEO Marc Tessier-Lavigne (ex-Stanford president, ex-Genentech CSO) and co-founder David Baker (Nobel laureate, UW Institute for Protein Design).
Business Model & Competitive Advantage
Xaira builds AI models predicting biological behavior at the cellular level to design novel therapeutics, initially targeting inflammatory and immunological diseases. X-Cell, unveiled March 2026, predicts gene function from genetic perturbations. Board includes former FDA Commissioner Scott Gottlieb and Nobel laureate Carolyn Bertozzi.
Competitive Landscape 2025–2026
Investors include F-Prime, NEA, Sequoia, Lux Capital, and Lightspeed. Pre-revenue, focused on building AI platform, proprietary datasets, and advancing antibody therapy programs toward clinical development.
Recent Activity
View all →Key Differentiators
Strong Challenger
Xaira Therapeutics is an established challenger with significant market presence and competitive offerings in Healthcare & Life Sciences.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Compare Xaira Therapeutics with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Xaira Therapeutics? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Xaira Therapeutics Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Xaira Therapeutics vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →